Questions and responses 45th Parliament, 1st session May 26, 2025, to present

With regard to the World Health Organization Pandemic Agreement: has the government signed the binding World Health Organization Pandemic Agreement, who actually signed it or will sign it and on what date?

With regard to Health Canada's regulation of the modRNA COVID-19 vaccines: (a) what information does Health Canada possess on the identity of the facility or facilities responsible for manufacturing, linearizing and quality-controlling the plasmid DNA template used to produce mRNA for the authorized COVID-19 vaccines; (b) what inspections of the manufacturing facilities did Health Canada perform regarding manufacturing, testing and release of the linear DNA template that formed the starting material for the COVID-19 mRNA vaccines, and which manufacturers or vendors and sites were inspected, when and by whom; (c) if the inspections in (b) were not done, why not; (d) what quality assessment was performed with the sponsors (Pfizer Canada ULC or BioNTech SE) concerning the control of the linear DNA template, its plasmid source and the outsourcing of its production by (i) Canadian authorities, (ii) other regulators who shared the results with Canadian authorities; (e) did Health Canada determine if there were deficiencies, open questions or site qualifications related to the linear DNA template or plasmid manufacturing process, and, if so, what was the outcome, or, if not, why not; (f) were the linearization and residual DNA removal processes required to comply with standards in (i) ICH Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (with respect to residual DNA limits and characterization), (ii) ICH Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products, (iii) USP <1047> and <1049>: Gene Therapy Products and DNA Templates-Residual DNA Testing and Limits; (g) if the answer to (f) is negative, why not; (h) is Health Canada aware of any shared or outsourced master plasmid cell bank stock arrangements between (i) Pfizer and other entities, (ii) Moderna and other entities, to produce mRNA templates across multiple facilities or jurisdictions; (i) has Health Canada received any deviation reports, corrective and preventive action plans, or lot investigations relating to incomplete linearization in (i) Pfizer's, (ii) Moderna's, COVID-19 vaccine drug substance or finished product; and (j) if the answer to (i) is affirmative, what were the dates and findings of those reports, and were any product quality complaints or safety concerns escalated to the Biologic and Radiopharmaceutical Drugs Directorate?

With regard to communications sponsored by the government during the COVID-19 pandemic: (a) which individual or agency developed the “Pregnancy, childbirth and caring for a newborn during the COVID-19 pandemic” communication, which was first published on July 13, 2021, and last updated on October 25, 2023; (b) who provided the final approval of the communication in (a) and when; (c) which individual or agency developed the narrative for the video titled, “Are there any ingredients in the COVID-19 vaccines that I should be concerned about”, narrated by Dr. Ayesha Raza; (d) who provided the final approval of the communication in (c) and when; (e) which individual or agency developed the narrative for the video titled, “Can the COVID-19 vaccines affect fertility”, narrated by Dr. Darine El-Chaâr; (f) who provided the final approval of the communication in (e) and when; (g) on December 23, 2021, which individual or agency developed the advice to Canadians about the interchangeability of vaccines found on the government's website, titled, “COVID-19 vaccine: Canadian Immunization Guide, For health professionals, Notice”; and (h) who provided the final approval of the communication in (g) and when?

With regard to the Public Health Agency of Canada and Health Canada COVID-19 pandemic response: (a) did the Public Health Agency of Canada or Health Canada conduct, assign or fund random representative national seroprevalence surveys for SARS-CoV-2 during the pandemic; (b) if the answer to (a) is affirmative, for each survey, (i) what was the name of the agency or institutions that did the testing, (ii) what were the dates of the testing, (iii) what were the results stratified by age and region; (c) if the answer to (a) is affirmative, what were the age stratified infection fatality rates based on this data; (d) if the answer to (a) is affirmative, (i) what was the primary test used for serological detection, (ii) how was it independently validated for sensitivity and specificity, (iii) was it primarily used with dry blood samples; (e) if the answer to (a) is affirmative, (i) was any other SARS-CoV-2 protein tested for antibodies besides the nucleocapsid or spike protein, (ii) were the following antibodies assayed: IgG1, IgG3, IgA, and IgM; (f) if the Public Health Agency of Canada or Health Canada did not conduct, assign or fund random, representative national seroprevalence surveys for SARS-CoV-2 during the pandemic, why not; and (g) why did the Government of Canada appoint an external Immunity Task Force to conduct serosurveys rather than leveraging internal research personnel, existing research partnerships and rapid research protocols, as published in the Canadian Influenza Pandemic Plan 2018, which is not confined to influenza pandemics?

With regard to Health Canada and Public Health Agency of Canada messaging about the safety of COVID-19 vaccines during pregnancy and lactation and website messaging that reads, “Vaccination is an important part of a healthy pregnancy, with health benefits for both the pregnant person and their baby. Several vaccines are routinely recommended during pregnancy, including COVID-19 vaccines [...] Evidence suggests that COVID-19 vaccination during pregnancy helps to prevent: COVID-19 infection and the risk of hospitalization from COVID-19 in infants under 6 months of age” and the government response to Order Paper Question Q-2163 from the 44th Parliament, which reads, “As indicated in the specific Product Monographs, it is noted that the safety and efficacy of these vaccines in pregnant women have not yet been established. No indication for use in pregnant or lactating women was sought by the vaccine sponsors or authorized by Health Canada [...] Health Canada has not approved any safety claims with regard to pregnant and lactating women”: (a) how does Health Canada and the Public Health Agency of Canada explain these two conflicting statements; (b) who wrote the statement on the government's website and who approved it; and (c) who wrote the statement in the response to Q-2163 and who approved it?

With regard to all payments made since May 5, 2023, from COVID-19 income support programs for workers, including the Canada Emergency Response Benefit, the Canada Recovery Benefit, the Canada Recovery Caregiving Benefit, the Canada Recovery Sickness Benefit and the Canada Worker Lockdown Benefit: (a) what is the total amount paid to Canadians under each program; (b) how many individuals have received payments under each program; (c) what was the average amount paid per recipient under each program; (d) what is the total amount of overpayments identified, under each program, and how much has been recovered to date; and (e) how many cases of suspected or confirmed fraud related to these programs have been investigated or referred to law enforcement, including the total dollar value associated with each such case?

With regard to Health Canada’s review of the COVID-19 modRNA vaccine products: (a) did Health Canada consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if the answer to (a) is affirmative, what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did Health Canada assess the toxicity of pegylated nanoparticles, specifically the risk for complement activation-related pseudoallergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if the answer to (d) is affirmative, why was this not included in the product labelling; (f) if the answer to (d) is negative, why wasn’t this assessed; (g) did Health Canada assess the risk of toxicity due to the nanoformat of these vaccines; (h) if the answer to (g) is affirmative, what was the assessment result; (i) if the answer to (g) is negative, why not; (j) did Health Canada assess the lipid nanoparticles as a novel excipient; (k) if the answer to (j) is affirmative, what was the assessment; (l) if the answer to (j) is negative, why not; (m) with respect to nanotechnology products and their unique properties and behaviours, particularly in their application to the modRNA vaccines, did Health Canada examine (i) the safety, (ii) the effectiveness, (iii) the risk to the environment, (iv) its specific regulatory status; (n) if the answers to (m)(i) through (m)(iv) are affirmative, what were the assessment results; (o) if the answers to (m)(i) through (m)(iv) are negative, why not; (p) how do established safe levels of DNA apply (i) when using pegylated lipid nanoparticles as a delivery system, (ii) when a product that contains pegylated lipid nanoparticles requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated lipid nanoparticles as a delivery system in a vaccine which requires repeated dosing?

With regard to the Public Health Agency of Canada’s “Cases Following Vaccination” reports published from August 2021 to September 2022: (a) why did the Public Health Agency of Canada decide to begin calculating and comparing COVID-19 deaths using vaccination status, on the date of COVID-19 vaccine approval in December 2020, rather than the date on which each corresponding dose level actually began to be administered, or using weekly death counts, as is done for Statistics Canada’s Deaths by Age and Deaths by cause statistics; (b) what internal documentation, analyses, and external scientific or technical references were consulted to inform the methodological choice described in (a); (c) within the Public Health Agency of Canada, which organizational units and officials or governing authorities (i) proposed the methodology described in (a), (ii) reviewed it (including any internal methodological or ethics review), (iii) formally approved it for use in the “Cases Following Vaccination” reports; (d) in what way does the methodology described in (a) permit the observation and analysis of time-based (for example, weekly or seasonal) variations in COVID-19 deaths by vaccination status in relation to contemporaneous factors, including, but not limited to, seasonal changes and the dates on which additional vaccine doses (for example, second, third, or booster doses) began to be administered; and (e) in developing and approving this methodology, did the Public Health Agency of Canada rely on, or explicitly reference, any guidance, standards, or methodologies issued by the World Health Organization or any other international public health body, and, if so, which specific documents or authorities were relied upon?

With regard to Canada’s engagement with the World Health Organization's Pandemic Prevention, Preparedness and Response Agreement (the Agreement) and the amendments to the International Health Regulations: (a) what steps has the government taken to ensure parliamentary review before signing or ratifying the Agreement; (b) has Global Affairs Canada or the Privy Council Office prepared any analysis comparing Canada’s treaty ratification process with those of Australia or the United Kingdom regarding public health treaties, and, if so, what are the details, including the findings, of that analysis; (c) how does the government plan to align domestic laws with the Agreement, and which departments will have enforcement authority; and (d) how does the government plan to align domestic laws with the amendments to the International Health Regulations, and which departments will have enforcement authority?

With regard to the Public Health Agency of Canada, Health Canada, the National Advisory Committee on Immunization and COVID-19 vaccine deaths and injuries: (a) on what date did each government department first receive a report of a death from the (i) AstraZeneca, (ii) Pfizer, (iii) Moderna, COVID-19 vaccine; (b) what are the dates of the meetings in which the deaths from COVID-19 vaccines were discussed; (c) for each meeting in (b), what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting; (iv) names of process documents modified after the meeting; (d) did the Public Health Agency of Canada or Health Canada develop a subcommittee to address deaths from the COVID-19 vaccines, and, if so, (i) who was on this committee, (ii) how often did it meet, (iii) what are the dates of the meetings, (iv) what were the outcomes of these meetings, (v) what are the names of the documents associated with these meetings; (e) did a government department notify any Member of Parliament or their staff about deaths from COVID-19 vaccines, and, if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified; (f) on what date did a government department first receive a report of a spontaneous abortion from a COVID-19 vaccine; (g) what are the dates of the meetings discussing the spontaneous abortions in (f); (h) for each meeting in (g), what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting, (iv) names of process documents modified after the meeting; (i) did a government department notify any Member of Parliament or their staff about spontaneous abortions from COVID-19 vaccines, and, if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified; (j) on what date did a government department first receive a report of (i) a heart attack, (ii) a stroke, (iii) myocarditis, (iv) pericarditis from COVID-19 vaccines; (k) what are the dates of the meetings discussing the reports in (j); (l) for each meeting in (k) what are the (i) names of those who attended the meeting, (ii) titles of those who attended the meeting, (iii) conclusions reached during the meeting; (iv) names of process documents modified after the meeting; and (m) did a government department notify any Member of Parliament or their staff about heart attacks, strokes, myocarditis or pericarditis from COVID-19 vaccines, and if so, for each notification, (i) who was notified, (ii) how were they notified, (iii) on what date were they notified, (iv) what was the subject of the notification?

With regard to Health Canada, the Public Health Agency of Canada and the National Advisory Committee on Immunization and their statement, “the benefits of the COVID-19 vaccines outweigh the risks”: (a) what are the benefits of the COVID-19 vaccines, broken down by (i) benefit, (ii) supporting studies or documents and their published date, (iii) start and end dates of the benefit analysis, (iv) name and title of those who analyzed the benefit; (b) what are the risks of the COVID-19 vaccines, broken down by (i) risk, (ii) supporting studies or documents and their published dates, (iii) date on which the risk was identified, (iv) start and end dates of the risk analysis, (v) name and title of those who analyzed the risk; (c) was a risk and benefit analysis performed for each COVID-19 vaccine product; (d) if the answer to (c) is affirmative, (i) what are the start and end dates of each analysis, (ii) what are the differences between the product analysis results; (e) was a separate risk and benefit analysis performed for (i) various age groups, (ii) genders, (iii) pregnant women, (iv) the immunocompromised, (v) First Nations and Indigenous populations; (f) if the answer to (e) is affirmative, for each group in (e), what are the (i) start and end dates for each analysis performed, (ii) name and title of those who performed them; (g) was a risk and benefit analysis performed for Canadians who were previously infected with COVID-19; and (h) if the answer to (g) is affirmative, for each analysis performed, what (i) was the start date, (ii) was the end date, (iii) were the conclusions of the analysis?

With regard to COVID-19 vaccine procurement by the government: (a) how many COVID-19 vaccines has Canada (i) procured, (ii) had delivered, since the pandemic was declared over on May 5, 2023, in total and broken down by supplier; (b) how many vaccines have been ordered but not yet delivered, in total and broken down by supplier; (c) how much money has been spent on procuring the vaccines (i) procured, (ii) delivered, since May 5, 2023, in total and broken down by supplier; and (d) what is the government's estimate on how much it will spend on future purchases of COVID-19 vaccines, in total and broken down by supplier and year, if known?

With regard to the Canada Emergency Response Benefit: (a) what was the total value of (i) overpayments, (ii) payments made to ineligible recipients; (b) how many recipients received payments in (a)(i) and (a)(ii); (c) of the amounts in (a)(i) and (a)(ii), how much has been recovered to date, and from how many recipients; (d) how many recipients still have an outstanding balance due to (i) overpayment, (ii) ineligibility, and what is the total value of outstanding balances; (e) how much of the payments in (a)(i) and (a)(ii) has the Canada Revenue Agency written off, in total and broken down by reason (bankruptcy, death, recipient abroad, etc.); (f) how many (i) overpayments, (ii) payments made to ineligible recipients, were made to recipients who were not Canadian residents, and what was the total value of each type of payment; (g) of the instances of (i) overpayments, (ii) ineligibility, how many recipients appealed the determination of the Canada Revenue Agency, and what was the success rate of the appeals; and (h) how many appeals related to the payments in (a)(i) and (a)(ii) are still awaiting a ruling?

With regard to the response to Order Paper Question Q-763 and Health Canada, the Public Health Agency of Canada and the National Advisory Committee on Immunization, Canadian Institutes of Health Research, the National Research Council, and the costs and expenses associated with COVID-19 vaccine benefits and risks since January 2020: (a) how much money was spent investigating and researching the benefits of the COVID-19 vaccine, broken down by (i) month, (ii) expense or project name, (iii) start and end date, (iv) total cost, (v) description; (b) how much money was spent investigating and researching the risks and adverse effects of the COVID-19 vaccine, broken down by (i) month, (ii) expense or project name, (iii) start and end date, (iv) total cost, (v) description; (c) how much money was spent informing Canadians of the benefits of the COVID-19 vaccine, broken down by (i) expense name, (ii) date, (iii) cost, (iv) overview of expense; (d) how much money was spent informing Canadians about the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense name, (ii) date, (iii) cost, and (iv) overview of expense; (e) how much money was spent promoting the COVID-19 vaccines, including grants, working groups, research projects, contractors, advertising, influencers, surveys, publications and behavioural assessments, broken down by (i) type of promotion, (ii) expense, (iii) date, (iv) total cost, (v) description; (f) how much money was spent informing health professionals of the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) total cost, (iv) description; (g) how much money was spent informing Government of Canada employees, contractors, or federally regulated companies on the benefits of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) description; and (h) how much money was spent informing Government of Canada employees, contractors or federally regulated companies on the risks and adverse effects of the COVID-19 vaccine, broken down by (i) expense, (ii) date, (iii) description?

With regard to Crown-Indigenous Relations and Northern Affairs Canada and Indigenous Services Canada: (a) what investigations were undertaken before making the determination that First Nations and Indigenous peoples were designated a priority group to receive the COVID-19 vaccines; (b) who made the recommendation in (a), and who approved the determination; (c) has the Minister of Crown-Indigenous Relations or the Minister of Indigenous Services received any correspondence in the last five years from any First Nations or Indigenous tribunals, either Canadian or international, about the COVID-19 vaccines; (d) if the answer to (c) is affirmative, what was the content of the correspondence and what actions took place; (e) were investigations undertaken by Crown-Indigenous Relations and Northern Affairs Canada or by the Government of Canada to investigate the rates of adverse events, including fatalities, in the First Nations and Indigenous populations following the administration of the COVID-19 vaccine; (f) what information or conclusions were made from the investigations in (e); (g) what action did the Minister of Crown-Indigenous Relations or the Minister of Indigenous Services take to protect First Nations and Indigenous populations once it was discovered that the mRNA injections were contaminated with excess deoxyribonucleic acid combined with an SV40 nuclear targeting agent; (h) did Crown-Indigenous Relations and Northern Affairs Canada receive any funding to promote the COVID-19 vaccines to the First Nations and Indigenous population, and, if so, how much and from what source; (i) did any or all bands receive funding specifically in relation to the COVID-19 vaccine; (j) if the answer to (i) is affirmative, how much funding was received by each band, was the funding contingent on specific compliance regarding the COVID-19 vaccine or its promotion, and, if so, what were those conditions; (k) if the answer to (i) is affirmative, who or what agency provided the funding, and was any funding directed towards (i) preventing vaccine hesitancy, (ii) promoting awareness of adverse reactions, (iii) other, and how much was allocated for (i), (ii) and (iii); (l) in relation to the Vaccine Injury Support Program, (i) how many First Nations and Indigenous persons have applied to the Vaccine Injury Support Program, (ii) how many applications have been accepted, (iii) how many fatalities have been recorded in this population, (iv) how much money in total has been awarded through this program to First Nations and Indigenous persons; (m) if the answer to (l) is negative, is there another application process or vaccine injury support program specifically for First Nations and Indigenous persons who have suffered a vaccine injury or fatality; and (n) if the answer to (m) is affirmative, (i) what is the name of the program, (ii) how many First Nations and Indigenous persons have applied to this program, (iii) how many applications have been accepted, (iv) how many fatalities have been recorded in this population, (v) how much money in total has been awarded through this program?

With regard to the Canada Border Services Agency, Immigration, Refugees and Citizenship Canada, and the COVID-19 pandemic: (a) how many migrant workers entered Canada between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (b) what are the details of the quarantine period, including (i) how many migrant workers were quarantined, by province, (ii) when they were quarantined, by month and year, (iii) the length of the quarantine period, (iv) who paid for their quarantine accommodations, (v) the overall cost to the government; (c) how many migrant workers received their COVID-19 vaccine in Canada, upon their arrival in Canada between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (d) in cases where the migrant worker was already COVID-19 vaccinated in his or her country of origin, did Canadian immigration authorities document the date of vaccination and the vaccine brand for migrant workers, and what is the data; (e) in cases where the migrant worker received an unapproved COVID-19 vaccine brand prior to entry, would they require receipt of a Canadian approved brand upon entry; (f) following COVID-19 immunization, how many migrant workers (i) sought medical attention, (ii) were determined too ill to work, (iii) were hospitalized, (iv) died while in Canada; (g) for each case in (f)(i) to (f)(iv), how many occurrences were there between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022, broken down by province; (h) in cases where a migrant worker died following immunization, what were the causes of death; (i) with regard to persons in (h), were any autopsies performed on any deceased migrant workers; (j) if the answer to (i) is affirmative, how many autopsies were performed and what were the findings; (k) how many deceased bodies or their cremated remains were sent back to their country of origin between (i) April 1, 2020, and October 31, 2020, (ii) April 1, 2021, and October 31, 2021, (iii) April 1, 2022, and October 31, 2022; and (l) in cases where a migrant worker had an adverse event following their COVID-19 vaccination in Canada, would they qualify for Canada's Vaccine Injury Support Program?

With regard to Employment Insurance eligibility determinations related to employer COVID-19 vaccination policies: (a) what is the government’s position on whether an individual’s vaccination status, or refusal to disclose such status, constitutes “misconduct” under the Employment Insurance Act; (b) were any changes made, formal or informal, to the interpretation or application of “misconduct” or “just cause” in Employment Insurance decisions during or since the COVID-19 pandemic, and, if so, what were those changes and when were they implemented; (c) how many Employment Insurance claims were denied on the basis of “misconduct” related to vaccination policies, and what proportion of those cases included an assessment of “just cause”, broken down by year since COVID-19 vaccinations began; (d) what guidance, directives, or decision-making tools were provided to Service Canada or Social Security Tribunal decision-makers regarding Employment Insurance claims involving vaccination policies, and when was each provided; and (e) what steps, if any, has the government taken to review or reassess Employment Insurance decisions made in these cases to ensure compliance with the Employment Insurance Act, and when was each step taken?

With regard to the Public Health Agency of Canada and the government’s future health approach: (a) which agency, entities or ministries are involved in (i) the pandemic prevention, preparedness and response protocols, (ii) the One Health approach; (b) what is the One Health approach and where or how did it originate; (c) which bills are currently tabled or have been passed which would operationalize (i) Canada’s pandemic prevention, preparedness and response protocols, (ii) the One Health approach in Canada, (iii) any other World Health Organization or United Nations international health or pandemic treaties or agreements; (d) have staff already been hired or will staff be hired and trained to integrate the One Health approach into Canadian policy and legislation; (e) if the answer to (d) is affirmative, (i) where and under which department or agency will these employees work, (ii) where are these positions posted, (iii) what are the hiring criteria for these staff, (iv) who selects the staff, (v) how many positions exist or will be created; (f) what is the budget allocation to integrate the One Health approach; (g) are there training programs for nongovernmental professionals in One Health and, if so, where are they located; and (h) if the answer to (g) is affirmative, (i) how are the training programs funded, (ii) what are their goals, (iii) who instructs these courses, (iv) what are the requirements to instruct these courses, (v) how did the instructors obtain these requirements?

With regard to COVID-19 vaccine mandates for public service employees, contractors and temporary workers: (a) how many employees and temporary workers were terminated because they didn't have the COVID-19 vaccine, broken down by (i) department, (ii) role, (iii) employment type (full-time, temporary, contractor); (b) how many employees and temporary workers had their pay suspended because they didn't have the COVID-19 vaccine, broken down by (i) department, (ii) role, (iii) employment type (full-time, temporary, contractor); (c) were grievances filed against the government for the COVID-19 vaccine employment mandates; (d) if the answer to (c) is affirmative, for each grievance, (i) what is the department, (ii) what is the role, (iii) what is the grievance, (iv) what is the state of the grievance, (v) what is the amount of money paid to the employee, (vi) did the government apologize for their actions; (e) did the government receive religious exemption requests for the COVID-19 employment vaccine mandate; and (f) if the answer to (e) is affirmative, how many religious exemption requests were received, broken down by (i) department, (ii) result of the request, (iii) who reviewed the exemption request?

With regard to Health Canada, the Public Health Agency of Canada and reports of myocarditis and pericarditis following COVID-19 vaccination: (a) what is the standard operating procedure when an Adverse Event Following Immunization report containing a potential safety signal is received or identified; (b) what federal teams, working groups, contract companies and persons were responsible for requesting, receiving, reviewing and monitoring any Adverse Event Following Immunization reports with respect to myocarditis and pericarditis following the COVID-19 vaccines from (i) international sources, (ii) the provinces and territories; (c) after the information in (b) was received, what steps or actions were taken next, by whom, and on what date; (d) was the Public Health Agency of Canada or Health Canada notified of Adverse Event Following Immunization reports for myocarditis and pericarditis following COVID-19 vaccination, and, if so, for each notification, what was the (i) name of the notifier, (ii) title of the notifier, (iii) form of notification, (iv) name of the person who was notified, (v) date of the notification; (e) did the Public Health Agency of Canada or Health Canada receive the initial reports of myocarditis and pericarditis following COVID-19 vaccination from the Israeli Ministry of Health in February 2021, and, if so, (i) who received the notification, (ii) what was the date of the notification, (iii) what actions were taken after the notification, (iv) who authorized these actions, including their name, their title and the date of authorization; (f) for each communication between the Public Health Agency of Canada, Health Canada and all Public Health Agency of Canada or Health Canada COVID-19 task forces or working groups related to the Israeli Ministry of Health myocarditis and pericarditis safety signal notification, what was the (i) date, (ii) subject, (iii) type and content, of the communication; and (g) what communication related to the myocarditis and pericarditis safety signal occurred between the Public Health Agency of Canada, Health Canada or the Public Health Agency of Canada or Health Canada COVID-19 task forces and the COVID-19 vaccine manufacturer, including the (i) date, (ii) subject, (iii) type and content, of the communication?